Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Roginolisib works by blocking a protein called PI3K-delta. By blocking this protein, roginolisib may strengthen your immune system's ability to fight cancer cells. It is taken orally (by mouth).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to see if the drug pasireotide works well to treat prolactinomas. Prolactinomas are noncancerous pituitary gland tumors that make too much prolactin. Prolactin is a hormone that causes the body to make less estrogen and testosterone (sex hormones).
The purpose of this study is to see how well sotorasib works in people with advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS G12C gene. This mutation can cause cancer cells to grow. In addition, the people in this study have not received treatment for their cancer since it became advanced.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
In people born with certain genetic mutations or whose tumors have these mutations, the standard treatment for breast cancer with CDK4/6 inhibitors (like palbociclib, ribociclib, or abemaciclib) might not be as effective. However, their tumors may still respond to a different type of drug called PARP inhibitors.
The purpose of this study is to see if the combination of fianlimab, cemiplimab, and ipilimumab works well against melanoma. The people in this study have melanoma that is inoperable (cannot be taken out with surgery) or metastatic (spread). In addition, their cancer keeps growing even after treatment that included immunotherapy.
Deficient mismatch repair (dMMR) happens when a cell becomes unable to repair mistakes that happen during the normal process of cell division. Standard treatments for early-stage rectal cancer include chemotherapy, radiation therapy, and surgery. In this study, researchers are assessing the safety and effectiveness of giving the investigational immunotherapy dostarlimab first in people with locally advanced mismatch repair-deficient rectal cancer. Doctors will then evaluate patients' response to treatment before considering standard chemoradiation and/or surgery. Patients whose tumors respond completely to dostarlimab alone can be followed with close surveillance and no surgery. 
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
